| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company's venture with Dr. Alon Silberman that focuses on drug discovery and development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, has validated the potential significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer ("NSCLC") cells with diverse genetic backgrounds. MitoCareX demonstrated the discovery by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors.
NSCLC is the most typical form of lung cancer and, according to ResearchAndMarkets.com, the NSCLC Market is projected to reach a value of $59.77 billion by the year 2030. Accounting for 80%-85% of all lung cancer cases globally, NSCLC has driven key market players to focus on continuous innovation and efficacy enhancement in therapeutics. This prominence is due to lung cancer's status as one of the most common cancers worldwide, contributing to a significant number of global deaths.
Posted In: SPRC
